Hemogenyx Pharmaceuticals PLC Net Assets
Hemogenyx Pharmaceuticals PLC net assets. Based on the latest financial reports, Hemogenyx Pharmaceuticals PLC (HEMO) has net assets worth GBX-546.41K GBX (≈ $-66.48 USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX3.10 Million ≈ $377.33 USD) and total liabilities (GBX3.65 Million ≈ $443.82 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Hemogenyx Pharmaceuticals PLC equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX-546.41K |
| % of Total Assets | -17.62% |
| Annual Growth Rate | 30.48% |
| 5-Year Change | -2.53% |
| 10-Year Change | N/A |
| Growth Volatility | 434.38 |
Net Assets of Hemogenyx Pharmaceuticals PLC (2015–2024)
Net assets of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. This chart illustrates how Hemogenyx Pharmaceuticals PLC's net assets have evolved over time, based on quarterly financial data. See Hemogenyx Pharmaceuticals PLC (HEMO) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Hemogenyx Pharmaceuticals PLC (2015–2024)
The table below shows the annual net assets of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. For live market cap and overall valuation, see Hemogenyx Pharmaceuticals PLC stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX853.49K ≈ $103.85 |
-69.31% |
| 2023-12-31 | GBX2.78 Million ≈ $338.37 |
-14.26% |
| 2022-12-31 | GBX3.24 Million ≈ $394.64 |
-60.29% |
| 2021-12-31 | GBX8.17 Million ≈ $993.76 |
+832.71% |
| 2020-12-31 | GBX875.68K ≈ $106.55 |
+350.89% |
| 2019-12-31 | GBX-349.04K ≈ $-42.47 |
-136.39% |
| 2018-12-31 | GBX959.17K ≈ $116.70 |
-55.01% |
| 2017-12-31 | GBX2.13 Million ≈ $259.39 |
+135.90% |
| 2016-12-31 | GBX903.71K ≈ $109.96 |
+1061.28% |
| 2015-12-31 | GBX77.82K ≈ $9.47 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hemogenyx Pharmaceuticals PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3557553900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Hemogenyx Pharmaceuticals PLC Net Assets Breakdown (December 2024)
Hemogenyx Pharmaceuticals PLC net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX35.05K | 3.90% |
| Other Comprehensive Income | GBX1.07 Million | 119.51% |
| Other Components | GBX35.37 Million | 3941.07% |
| Total Equity | GBX897.51K | 100.00% |
Hemogenyx Pharmaceuticals PLC Competitors by Market Cap
The table below lists competitors of Hemogenyx Pharmaceuticals PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ALBERT LABS INTL. CORP.
F:VB50
|
$372.07K |
|
SU Group Holdings Limited Ordinary Shares
NASDAQ:SUGP
|
$372.83K |
|
PROPHECY DEFI INC.
F:V8M
|
$374.62K |
|
Global Gas Corporation
NASDAQ:HGAS
|
$378.40K |
|
LIVE MOTION GAMES ZY -10
F:4YM
|
$367.59K |
|
Metgasco Ltd
AU:MEL
|
$367.42K |
|
SysGroup PLC
LSE:SYS
|
$366.73K |
|
Nevada Zinc Corp
V:NZN
|
$366.25K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hemogenyx Pharmaceuticals PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,818,729 to 897,514, a change of -1,921,215 (-68.2%).
- Net loss of 5,619,181 reduced equity.
- New share issuances of 3,712,490 increased equity.
- Other comprehensive income increased equity by 6,143,370.
- Other factors decreased equity by 6,157,894.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-5.62 Million | -626.08% |
| Share Issuances | GBX3.71 Million | +413.64% |
| Other Comprehensive Income | GBX6.14 Million | +684.49% |
| Other Changes | GBX-6.16 Million | -686.11% |
| Total Change | GBX- | -68.16% |
Book Value vs Market Value Analysis
This analysis compares Hemogenyx Pharmaceuticals PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2096.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2114.85x to 2096.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | GBX0.27 | GBX570.00 | x |
| 2015-02-28 | GBX0.27 | GBX570.00 | x |
| 2015-12-31 | GBX0.48 | GBX570.00 | x |
| 2016-12-31 | GBX1.02 | GBX570.00 | x |
| 2017-12-31 | GBX3.28 | GBX570.00 | x |
| 2018-12-31 | GBX1.07 | GBX570.00 | x |
| 2019-12-31 | GBX-0.38 | GBX570.00 | x |
| 2020-12-31 | GBX0.86 | GBX570.00 | x |
| 2021-12-31 | GBX4.23 | GBX570.00 | x |
| 2022-12-31 | GBX1.34 | GBX570.00 | x |
| 2023-12-31 | GBX1.00 | GBX570.00 | x |
| 2024-12-31 | GBX0.27 | GBX570.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hemogenyx Pharmaceuticals PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -626.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 4.69x
- Recent ROE (-626.08%) is below the historical average (-155.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -14.34% | 0.00% | 0.00x | 1.00x | GBX-10.64K |
| 2015 | -14.34% | 0.00% | 0.00x | 1.00x | GBX-10.64K |
| 2015 | -232.43% | -2642.29% | 0.02x | 4.17x | GBX-188.66K |
| 2016 | -57.53% | 0.00% | 0.00x | 1.16x | GBX-610.27K |
| 2017 | -110.78% | 0.00% | 0.00x | 1.12x | GBX-2.57 Million |
| 2018 | -154.04% | 0.00% | 0.00x | 2.40x | GBX-1.57 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-1.42 Million |
| 2020 | -233.74% | 0.00% | 0.00x | 2.99x | GBX-2.17 Million |
| 2021 | -62.25% | 0.00% | 0.00x | 1.04x | GBX-5.92 Million |
| 2022 | -121.49% | 0.00% | 0.00x | 2.17x | GBX-4.31 Million |
| 2023 | -237.37% | 0.00% | 0.00x | 2.17x | GBX-6.97 Million |
| 2024 | -626.08% | 0.00% | 0.00x | 4.69x | GBX-5.71 Million |
Industry Comparison
This section compares Hemogenyx Pharmaceuticals PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $7,477,166
- Average return on equity (ROE) among peers: -144.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hemogenyx Pharmaceuticals PLC (HEMO) | GBX-546.41K | -14.34% | N/A | $371.82K |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $998.55K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $93.52K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $356.03K |
| Avacta Group PLC (AVCT) | $19.13 Million | -52.99% | 0.12x | $2.86 Million |
| BSF Enterprise Plc (BSFA) | $423.14K | -22.20% | 0.08x | $15.62K |
| Bioventix (BVXP) | $851.00K | 0.00% | 1.80x | $1.24 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $2.40 Million | -115.05% | 1.12x | $55.46K |
| CRISM Therapeutics Corporation (CRTX) | $23.48 Million | -13.39% | 0.12x | $81.89K |
| Fusion Antibodies PLC (FAB) | $16.32K | -695.70% | 18.23x | $72.60K |
| Faron Pharmaceuticals Oy (FARN) | $11.18 Million | -55.36% | 0.33x | $401.90K |
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more